{"id":"etonogestrel-ethinyl-estradiol-vaginal-ring","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vaginal irritation or discomfort"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Breakthrough bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etonogestrel is a progestin that suppresses the luteinizing hormone (LH) surge needed for ovulation, while ethinyl estradiol is an estrogen that provides cycle control and stabilizes the endometrium. Together, they create a hormonal contraceptive effect delivered directly through the vaginal mucosa, allowing for consistent systemic absorption over a 3-week cycle with a 1-week hormone-free interval.","oneSentence":"Etonogestrel and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus, providing contraceptive protection through a vaginal ring delivery system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:00.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception in women of reproductive age"}]},"trialDetails":[{"nctId":"NCT04257500","phase":"PHASE4","title":"Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS","status":"COMPLETED","sponsor":"Andrea Roe, MD, MPH","startDate":"2020-09-03","conditions":"Polycystic Ovary Syndrome","enrollment":22},{"nctId":"NCT02367846","phase":"PHASE4","title":"Assessing the Impact of Contraceptives on Bone Health Using 41Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Penn State University","startDate":"2015-01","conditions":"Other Disorders of Bone Development and Growth","enrollment":6},{"nctId":"NCT05994599","phase":"PHASE1","title":"Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring","status":"COMPLETED","sponsor":"Evestra Inc.","startDate":"2023-07-29","conditions":"Healthy Women, Female, Contraception","enrollment":36},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT01709318","phase":"PHASE2","title":"A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-12","conditions":"Contraception","enrollment":666},{"nctId":"NCT01490190","phase":"PHASE4","title":"Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-12-26","conditions":"Contraception","enrollment":252},{"nctId":"NCT02616146","phase":"PHASE3","title":"Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2015-12-01","conditions":"Contraception","enrollment":2016},{"nctId":"NCT04423068","phase":"EARLY_PHASE1","title":"Inpatient Adolescent Contraception","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2020-12-10","conditions":"Pregnancy Related, Contraception, Contraceptive Usage","enrollment":25},{"nctId":"NCT05360550","phase":"PHASE2","title":"A Study to Evaluate the Effect of a Contraceptive Vaginal Ring LSP- 5415 on Ovarian Function in Healthy Adult Females","status":"COMPLETED","sponsor":"Lupin Research Inc","startDate":"2022-07-05","conditions":"Pregnancy Prevention","enrollment":26},{"nctId":"NCT05360576","phase":"PHASE2","title":"An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study","status":"COMPLETED","sponsor":"Lupin Research Inc","startDate":"2022-02-24","conditions":"Pregnancy Prevention","enrollment":40},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT02367833","phase":"PHASE4","title":"Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis","status":"COMPLETED","sponsor":"Penn State University","startDate":"2015-01","conditions":"Bone; Disorder, Development and Growth","enrollment":60},{"nctId":"NCT02404038","phase":"NA","title":"A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods","status":"UNKNOWN","sponsor":"Desmond Tutu HIV Centre","startDate":"2015-07","conditions":"HIV","enrollment":131},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT03120728","phase":"PHASE4","title":"Application for the Etonogestrel/Ethinyl Estradiol Ring","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2017-07-10","conditions":"Emergency Contraception, Healthy, Reproductive Age Women","enrollment":36},{"nctId":"NCT02529683","phase":"NA","title":"Study of Nuvaring Acceptability, Adherence and Biological Effects Among HIV-negative Women in Kenya","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Hormonal Contraception","enrollment":200},{"nctId":"NCT01638767","phase":"PHASE4","title":"NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles","status":"TERMINATED","sponsor":"Clinique Ovo","startDate":"2012-07","conditions":"Infertility","enrollment":7},{"nctId":"NCT01813162","phase":"PHASE1","title":"In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products","status":"COMPLETED","sponsor":"CONRAD","startDate":"2013-12","conditions":"HIV Prevention","enrollment":101},{"nctId":"NCT01796613","phase":"PHASE2, PHASE3","title":"Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2013-06","conditions":"Contraception","enrollment":120},{"nctId":"NCT00612508","phase":"NA","title":"Hormonal Contraception and Vaginal Health","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptive Usage, Vaginal Epithelial Disruption","enrollment":14},{"nctId":"NCT01448291","phase":"PHASE4","title":"Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers","status":"UNKNOWN","sponsor":"Eastern Virginia Medical School","startDate":"2011-10","conditions":"Vaginosis, Bacterial","enrollment":30},{"nctId":"NCT01087879","phase":"NA","title":"The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2007-10","conditions":"Contraception","enrollment":45},{"nctId":"NCT01384331","phase":"PHASE4","title":"New Treatments for Troublesome Bleeding in Implanon Users","status":"UNKNOWN","sponsor":"Family Planning Association New South Wales","startDate":"2011-07","conditions":"Menstrual Problem","enrollment":200},{"nctId":"NCT00475553","phase":"NA","title":"Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®","status":"COMPLETED","sponsor":"Scott and White Hospital & Clinic","startDate":"2006-05","conditions":"Breakthrough Bleeding, Breakthrough Spotting","enrollment":75},{"nctId":"NCT00269620","phase":"PHASE4","title":"PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-06","conditions":"Contraception","enrollment":500}],"_emaApprovals":[],"_faersSignals":[{"count":35,"reaction":"PULMONARY EMBOLISM"},{"count":17,"reaction":"DEEP VEIN THROMBOSIS"},{"count":8,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":7,"reaction":"ANXIETY"},{"count":7,"reaction":"DEPRESSION"},{"count":6,"reaction":"HEADACHE"},{"count":5,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":5,"reaction":"MUSCLE SPASMS"},{"count":5,"reaction":"OFF LABEL USE"},{"count":5,"reaction":"WEIGHT INCREASED"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NuvaRing"],"phase":"marketed","status":"active","brandName":"Etonogestrel/ethinyl estradiol vaginal ring","genericName":"Etonogestrel/ethinyl estradiol vaginal ring","companyName":"Andrea Roe, MD, MPH","companyId":"andrea-roe-md-mph","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etonogestrel and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus, providing contraceptive protection through a vaginal ring delivery system. Used for Contraception in women of reproductive age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}